Lesch-Nyhan Disease Workup

  • Author: H A Jinnah, MD, PhD; Chief Editor: Amy Kao, MD   more...
 
Updated: Feb 23, 2012
 

Approach Considerations

In patients with Lesch-Nyhan disease, uric acid levels in the blood and urine are typically increased. Definitive diagnosis is generally obtained by measurement of the hypoxanthine-guanine phosphoribosyl transferase (HPRT) enzyme. Confirmation of the diagnosis is most reliably made by identification of the HPRT gene.

Next

Lab Studies

The gross overproduction of uric acid is often evident in routine blood and urine studies.[2] Uric acid levels in the blood typically are elevated, a helpful clue that can be obtained by routine clinical testing; however, hyperuricemia has many different causes, and some patients with Lesch-Nyhan disease have serum uric acid levels in the normal range. As a result, serum uric acid levels do not provide reliable diagnostic information.

A 24-hour urine sample typically demonstrates a marked increase of uric acid over normative values, particularly if corrected for patient weight. However, 24-hour samples are notoriously difficult to collect. Calculation of the concentration ratio of urinary uric acid to creatinine in a spot urine specimen provides an alternative method, though less information is available concerning normative values. Hyperuricosuria is neither sensitive enough nor specific enough to provide reliable diagnostic information.

Definitive diagnosis is obtained most often by measurement of HPRT enzyme activity in blood or tissue. Blood samples often are used, though intact fibroblasts or lymphocytes provide more precise information with prognostic implications.

Diagnosis is confirmed by identifying a molecular genetic mutation in the HPRT gene. Molecular genetic diagnosis provides an ideal tool for carrier detection and prenatal screening of at-risk pregnancies.

Macrocytic anemia, sometimes profound, is relatively common. Vitamin B-12, folate, and iron levels are typically normal.

Previous
Next

Imaging Studies

Neuroimaging studies of the brain, by CT scan and MRI, generally do not reveal obvious structural malformations or signal changes in patients with Lesch-Nyhan disease.[3] They may reveal mild loss of brain volume, but this loss is often so small that it escapes notice in routine imaging studies.

Neuroimaging studies of the spinal cord, particularly the cervical portions, may reveal early degenerative joint disease that can damage the spinal cord or emerging nerve roots.

Noninvasive imaging studies of the kidneys and other parts of the urogenital system are warranted because of the marked increase in the risk of kidney stones. Any patient who develops flank pain, hematuria, or recurrent urinary tract infections should be evaluated. Some authorities have recommended yearly investigations in all patients, because asymptomatic stones or sludge may silently compromise renal function. Since stones composed of uric acid, oxypurine metabolites, or allopurinol are typically radiolucent, they may be invisible on plain films; however, they are imaged easily by renal ultrasonography.

Previous
 
 
Contributor Information and Disclosures
Author

H A Jinnah, MD, PhD  Professor, Departments of Neurology, Human Genetics, and Pediatrics, Emory University School of Medicine

H A Jinnah, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, Movement Disorders Society, and Society for Neuroscience

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD  Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society

Disclosure: Nothing to disclose.

Additional Contributors

Robert J Baumann, MD Professor of Neurology and Pediatrics, Department of Neurology, University of Kentucky College of Medicine

Robert J Baumann, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, and Child Neurology Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. Apr 1964;36:561-70. [Medline].

  2. Jinnah HA, Friedmann T. Lesch-Nyhan disease and its variants. In: Scriver CR, Sly WS, Childs B, Beaudet AL, et al, eds. The Molecular and Metabolic Bases of Inherited Disease. 6th ed. New York, NY: McGraw-Hill; 2000:Chapter 107.

  3. Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain. May 2006;129(Pt 5):1201-17. [Medline].

  4. Jinnah HA, Ceballos-Picot I, Torres RJ, Visser JE, Schretlen DJ, Verdu A, et al. Attenuated variants of Lesch-Nyhan disease. Brain. Feb 22 2010;[Medline].

  5. Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev. Apr 2000;32(2-3):449-75. [Medline].

  6. Jinnah HA, De Gregorio L, Harris JC, et al. The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res. Oct 2000;463(3):309-26. [Medline].

  7. Fu R, Jinnah HA. Genotype-Phenotype Correlations in Lesch-Nyhan Disease: Moving Beyond the Gene. J Biol Chem. Dec 7 2011;[Medline].

  8. Neychev VK, Jinnah HA. Sudden death in Lesch-Nyhan disease. Dev Med Child Neurol. Nov 2006;48(11):923-6. [Medline].

  9. Alford RL, Redman JB, O'Brien WE, et al. Lesch-Nyhan syndrome: carrier and prenatal diagnosis. Prenat Diagn. Apr 1995;15(4):329-38. [Medline].

  10. Nyhan WL, Vuong LU, Broock R. Prenatal diagnosis of Lesch-Nyhan disease. Prenat Diagn. Oct 2003;23(10):807-9. [Medline].

  11. Deon LL, Kalichman MA, Booth CL, Slavin KV, Gaebler-Spira DJ. Pallidal Deep-Brain Stimulation Associated With Complete Remission of Self-injurious Behaviors in a Patient With Lesch-Nyhan Syndrome: A Case Report. J Child Neurol. Sep 22 2011;[Medline].

Previous
Next
 
Purine metabolic pathways.
A small portion of the lower lip has been disfigured by persistent self-biting.
The distal portions of several fingers are shortened by prior uncontrolled self-biting.
The HPRT gene has 9 exons, with the coding region depicted as light gray boxes. Genetic mutations in Lesch-Nyhan disease and its variants are heterogenous and include point mutations leading to amino acid substitution (yellow circles), point mutations leading to premature stop (red squares), insertions (blue triangles), deletions (white lines), and other more complex changes (not shown).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.